





## 9th Annual Interdisciplinary PROSTATE CANCER Congress®

AND OTHER GENITOURINARY MALIGNANCIES

### OVERVIEW

The **New York GU™**: 9th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is an intensive, interactive, one-day educational program that brings together renowned national experts in the fields of genitourinary malignancies treatment.

The Congress will focus on key clinical topics in the management of genitourinary malignancies, including prognostic/predictive markers in care, proactive methods to mitigate predictable treatment-related side effects, optimal use of chemotherapeutic strategies, androgen deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies, as well as exploring emerging data on various combinations and sequences of treatment strategies currently undergoing clinical trial evaluation. This year, there will be a particular and expanded focus on bladder cancer and renal cell carcinoma, given recent practice-changing developments that are altering the therapeutic landscape in these fields of care. Key questions concerning the application of landmark clinical trial data on emerging targeted and immunotherapeutic options, as well as the application of evolving biomarkers for these tumors, will be answered during expanded sessions on these topics this year.

This year's **New York GU™** meeting is not to be missed! The program is sure to continue its legacy and tradition to provide clinicians with the knowledge and confidence to maintain state-of-the-art care, and optimize outcomes for patients with genitourinary malignancies.

### TARGET AUDIENCE

This educational activity is directed toward medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with genitourinary malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of genitourinary malignancies may also participate.

### ACCREDITATION/DESIGNATION OF CREDIT

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.0 Contact Hours.

Register before January 31, 2016 and save \$25  
Use code: **P16BR1**

\*Discount available for physicians only

### CO-CHAIRS

#### Daniel P. Petrylak, MD

Professor of Medicine, Medical Oncology  
Director, Prostate and GU Medical Oncology  
Director, Prostate Cancer Translational  
Research Program  
Yale Cancer Center  
New Haven, CT

#### Leonard G. Gomella, MD, FACS

The Bernard W. Godwin Professor of  
Prostate Cancer  
Chairman, Department of Urology  
Associate Director, Jefferson Kimmel  
Cancer Center  
Clinical Director Jefferson Kimmel  
Cancer Center Network  
Thomas Jefferson University  
Philadelphia, PA

### FACULTY

#### E. David Crawford, MD

Professor of Urologic and Radiation Oncology  
Head of the Section of Urologic Oncology  
University of Colorado at Denver  
University of Colorado Hospital  
Chairman and Founder Prostate  
Conditions Education Council  
Denver, CO

#### Robert Dreicer, MD, MS, FACP, FASCO

Division of Hematology and Oncology  
Department of Medicine  
University of Virginia School of Medicine  
Charlottesville, VA

#### Celestia S. Higano, MD, FACP

Professor, Medicine and Urology  
University of Washington  
Seattle, WA

#### Toni Choueiri, MD

Clinical Director, Lank Center for  
Genitourinary Oncology  
Director, Kidney Cancer Center  
Senior Physician, Dana-Farber Cancer Institute  
Associate Professor of Medicine, Harvard  
Medical School  
Boston, MA

#### A. Oliver Sartor, MD

Laborde Professor of Cancer Research  
Medicine and Urology Departments  
Tulane University School of Medicine  
New Orleans, LA

#### Richard G. Stock, MD

Clinical Professor, Radiation Oncology  
Icahn School of Medicine at Mount Sinai  
New York, NY

#### Mario Sznol, MD

Professor of Medicine (Medical Oncology)  
Yale School of Medicine  
Clinical Research Program Leader,  
Melanoma Program  
Co-Director of Yale SPORE in Skin Cancer  
Yale Cancer Center  
New Haven, CT

### ACCOMMODATIONS

#### Crowne Plaza® Times Square Manhattan

Our location in the heart of New York gives our Broadway hotel guests easy access to Central Park, fabulous shopping, and the endless delights of the Big Apple. The verve of Times Square is just outside our front door. Unrivalled service can lead you to the city's hidden gems and world-famous institutions like MoMA and the Met. The Crowne Plaza® Times Square Manhattan hotel is waiting to welcome you to the Big Apple.

To make a reservation, call (888) 233-9527.  
When booking, please mention **PER®**  
**Interdisciplinary Prostate Cancer Congress®**  
to receive the discounted group rate.

# Saturday, March 19, 2016

Crowne Plaza® Times Square Manhattan  
New York, NY

7:00 AM Registration and Continental  
Breakfast

8:00 AM Welcome  
Daniel P. Petrylak, MD

### PROSTATE CANCER

8:05 AM Pre-session Survey

8:10 AM Current Perspectives on  
Prostate Cancer Screening:  
Every Male Above a Certain  
Age, Some, None?  
Leonard G. Gomella, MD, FACS

8:30 AM Localized Prostate Cancer  
E. David Crawford, MD

8:50 AM Integrating Molecular Markers  
into Decision Making for  
Prostate Cancer Treatment  
Leonard G. Gomella, MD, FACS

9:10 AM Challenging Case Debates:  
Active Surveillance vs Early  
Treatment  
Leonard G. Gomella, MD, FACS

9:35 AM BREAK

10:00 AM The Changing Treatment  
Landscape for Advanced and  
Castration-Resistant Prostate  
Cancer: The Evolving Role of  
Chemotherapy  
Daniel P. Petrylak, MD

10:20 AM The Changing Treatment  
Landscape for Advanced and  
Castration-Resistant Prostate  
Cancer: Optimal Use of Next  
Generation Anti-Androgen  
Therapies  
Robert Dreicer, MD

10:40 AM Updates in Radiation Therapy  
Strategies for the Treatment of  
Prostate Cancer  
Richard G. Stock, MD

11:00 AM Novel Therapies:  
Radiopharmaceuticals for  
Castration-Resistant Prostate  
Cancer  
Oliver Sartor, MD

11:20 AM Integrating Immunotherapy in  
the Management of Castration-  
Resistant Prostate Cancer  
Celestia S. Higano, MD, FACP

11:40 AM Post-session Survey

11:45 AM Panel Question-and-Answer  
Session

12:05 PM Challenging Case Debates: Best  
Practices for Advanced Disease  
Daniel P. Petrylak, MD

12:30 PM BREAK FOR LUNCH

1:45 PM Keynote Address  
TBA

### OTHER GU: RENAL CELL AND BLADDER CARCINOMAS

2:30 PM Pre-session Survey

2:35 PM Impacting Signaling Pathways to  
Treat Renal Cell Carcinoma  
Toni Choueiri, MD

2:55 PM Emerging Immunotherapies for  
Renal Cell Carcinoma  
Mario Sznol, MD

3:15 PM Immunotherapy in Bladder  
Cancer  
Daniel P. Petrylak, MD

3:35 PM Biomarkers for Renal Cell  
Carcinoma and Bladder Cancer  
TBA

3:55 PM Post-session Survey

4:00 PM Panel Question-and-Answer  
Session

4:20 PM Challenging Case Debates: Best  
Practices for RCC and Bladder  
Cancers  
• Who is most appropriate  
for immunotherapy?  
• Optimal sequence  
of agents  
Leonard G. Gomella, MD, FACS

4:45 PM Summary of the Day and  
Conclusions  
Leonard G. Gomella, MD, FACS

4:50 PM Adjournment

For more information and  
registration, visit us at

**gotoper.com**